Financial statements are reported in CHF. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
ACIU — AC Immune SA
CHF 1.79
CHF -0.01 (-0.47%)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Market Cap
CHF 177.51M
Forward P/E
3.8x
52-Week Range
N/A
ACIU Price History
Revenue vs. Net Income
CHF 3.6M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-CHF 70.2M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-118.0%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
25.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.9%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
